Engineered immune cells take on Hard-to-Treat prostate cancer

NCT ID NCT05022849

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times

Summary

This early-phase study tested a new treatment called JNJ-75229414 for men with a type of advanced prostate cancer that no longer responds to hormone therapy. The treatment uses the patient's own immune cells, modified to target a protein on cancer cells. The main goals were to find a safe dose and check for side effects in 15 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Cancer Center

    Duarte, California, 91010, United States

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • Levine Cancer Institute

    Charlotte, North Carolina, 28204, United States

  • Norton Cancer Institute

    Louisville, Kentucky, 40207, United States

  • University Of Minnesota

    Minneapolis, Minnesota, 55455, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • University of Utah Huntsman Cancer Institute

    Salt Lake City, Utah, 84112, United States

Conditions

Explore the condition pages connected to this study.